// App-Quantinova.ai

5028 : Clinical characteristics of metastatic castration resistant prostate cancer (mCRPC) patients with DNA repair (DNAr) defects.

Researchers

Presenter

  • Michael Kolinsky

Principal Investigators

  • Joaquin Mateo

  • Semini Sumanasuriya

  • Pasquale Rescigno

  • Diletta Bianchini

  • Zafeiris Zafeiriou

  • Raquel Perez Lopez

  • Nina Tunariu

  • Niven Mehra

  • Anuradha Jayaram

  • Suzanne Carreira

  • Susana Miranda

  • Penelope Flohr

  • Ruth Riisnaes

  • Jane Goodall

  • Gunther Boysen

  • Johann S. De Bono

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • The Institute of Cancer Research, Sutton, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Institute for Cancer Research, London, United Kingdom

  • Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom

  • St James Hospital, Kilmainhani, Ireland

  • Cancer Biomarkers Laboratory, The Institute of Cancer Research, London, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

Locations

  • Ireland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved